Castle Creek Biosciences Scoops Up $75M Back to HomeEXTON, PA, Castle Creek Biosciences, a gene therapy company, announced that it has received a new investment of $75 million to support the advancement of its clinical development pipeline.

Castle Creek Biosciences is leveraging its proprietary technology platform and commercial-scale manufacturing infrastructure to develop personalized gene therapies for rare diseases with high unmet needs.

About Castle Creek Biosciences, Inc.Castle Creek Biosciences is a privately held company that develops and commercializes gene therapies for patients with rare and serious genetic diseases.

In addition, Castle Creek Biosciences is developing FCX-013, a gene therapy for the treatment of moderate to severe localized scleroderma.

Castle Creek Biosciences is a portfolio company of Paragon Biosciences. | To read full story, visit https://startuparound.com/read/1585256407.3801794/Castle-Creek-Biosciences-Scoops-Up-$75M?ref=audio_experience